SEC Form 4 · accession 0001437749-15-000929
Oxford Immunotec Global PLC · OXFD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeff R. Schroeder
Officer — Chief Commercial Officer
Period of report
Jan 16, 2015
Accepted (ET)
Jan 21, 2015 · 4:46 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001586049
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share Option (Right to Buy)F1,F2 | $14.57 | Jan 16, 2015 | A | 18,513 | A | — | Jan 16, 2025 | Ordinary Shares | 18,513 | 18,513 | D |
Explanation of responses
- F1Option granted under Issuer's 2013 Share Incentive Plan.
- F2Options will become exercisable ratably on the first day of each month from February 1, 2015 through January 1, 2019.